Puma Biotechnology | PBYI - Cost Of Sales


Puma Biotechnology reported $29.1M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Daiichi Sankyo JPY 124.29B 6.02B Jun/2026
Exelixis USD 20.66M 704K Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Incyte USD 104.96M 457K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Moderna USD 93M 862M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Takeda JPY 517.6B 42.94B Jun/2026
TG Therapeutics USD 41.19M 7.68M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026